No Detail Found!

Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients.

Author(s)
Muhammad Ikhlaq Rawalpindi Medical College, Rawalpindi, Pakistan
Maryam Jalil THQ Hospital, Fateh Jang, Pakistan
Syed Dawar RMU Allied Hospitals, Rawalpindi, Pakistan
Muhammad Ashraf RMU Allied Hospitals, Rawalpindi, Pakistan
Abstract
Background: Sofosbuvir is on the world organization's list of essential medicines, the most effective and safe medicines needed in health system. It plays a special role in treatment of chronic hepatitis C and offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance. Objectives: To compare the treatment response in treatment naive and treatment experienced chronic hepatitis C patients treated with sofosbuvir and ribavirin to determine the efficacy of this drug combination. Methods: In this experimental study 104 chronic hepatitis C patients with positive polymerase chain reaction (PCR) for hepatitis C virus (HCV) and high alanine aminotransferase (ALT) levels were included. Out of them 66 (63.5%) were treatment naive (received treatment for the first time) and 38 (36.5%) were treatment experienced. Sofosbuvir 400mg once a day in combination with ribavirin was given for 6 months and treatment responses were noted at 4, 12 and 24 weeks. SPSS version 21 was used to analyze the data. Results: The end treatment response in 104 chronic hepatitis C patients was calculated in which 99 (95.2%) patients responded to the therapy. 63 (95.5%) treatment naive patients and 36 (94.7%) treatment experienced responded to the therapy. End treatment response (ETR) in chronic hepatitis C patients to sofosbuvir and ribavirin was irrespective to their gender and genotypes and test of significance came out as insignificant (p > 0.05). Conclusion: Sofosbuvir is effective for both treatment naive and treatment experienced chronic hepatitis C patients. This regimen is equally effective for both genders and all genotypes of hepatitis C.
Publication Details
Page(s) 19-22
DOI DOI not available
Published Journal: Journal of Rawalpindi Medical College, Volume: 22, Issue: S1, Year: 2018

Request the full text from PASTIC

0

Citations

0

Downloads

68

Views